Mortality secondary to bleeding within 30 days of surgery – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Surgical site infection · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of surgical site infections (SSIs) before discharge compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Number of major adverse effects defined by the study, before discharge · women with urinary stress incontinence undergoing continence surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of symptomatic UTIs or bacteriuria before discharge · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of symptomatic UTIs or bacteriuria before discharge compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Febrile morbidity · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of women with febrile morbidity at hospital discharge compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Number of women with sepsis or bacteraemia at hospital discharge · women with urinary stress incontinence undergoing continence surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mesh exposure · women with urinary stress incontinence undergoing continence surgery
It is very uncertain whether prophylactic antibiotics (single or combined drugs) changes number of mesh exposures within six weeks after the operation compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Participants with ≥ 1 vomiting episode · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in vomiting (≥1 episode) compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in nausea (≥1 episode) compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of vomiting episodes · adults receiving intravenous opioids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea severity · adults receiving intravenous opioids
1 finding from 1 review
Use of rescue medication · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in rescue medication compared with placebo (low certainty).
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Quality of life ‐ not reported · People with a haematological disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found